Delivery Order SPE2DB22D2214-SPE2DB24FS4XM
Award Date 5/16/24
Potential Completion Date 5/17/24
Potential Value $8K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,986.86, is for the delivery of Topamax 100 mg tablets. This is a firm fixed-price delivery order contract with an ultimate completion date of April 14, 2025. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a significant...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Topamax 50mg tablets. The contract has a ceiling value of $3,829.30 and a period of performance through August 2024. It is a firm-fixed-price contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, a primary vehicle...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation. The $5,788.52 firm fixed price delivery order is for the provision of Topamax 200 mg tablets. The contract has a completion date of February 6, 2024. This award is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 and a performance period through December 31,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distribution company, for the delivery of Topamax 200 mg tablets. The contract, valued at $53,458.02, is a firm fixed-price delivery order that does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp is a subsidiary of Cencora, Inc., which holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of Topamax 50 mg tablets. The contract has a ceiling value of $3,118.74 and a period of performance through April 1, 2024. AmerisourceBergen Drug Corp is the prime contractor and will deliver the pharmaceutical product from its corporate office in Conshohocken, Pennsylvania. This award is part of a larger indefinite...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, through its Corporate Office division, as the prime contractor. The contract has a delivery order structure with a firm fixed price pricing type, a ceiling value of $20,033.83, and a period of performance through April 2, 2024. The contract is for the delivery of Topamax 50 mg tablets in 60-count packages. No set-aside designation was used. AmerisourceBergen Drug Corp is also the prime...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) for the delivery of TOPAMAX 50 MG TABLET 60S. The contract has a ceiling value of $4,560.69 and is a Firm Fixed Price Delivery Order that runs through February 26, 2024. The contract award is not associated with any set-aside designations, indicating open competition. Amerisourcebergen holds a significant Indefinite...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,109.99 fixed-price delivery order contract is for the supply of TOPAMAX 50 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of March 8, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,606.98 firm fixed-price delivery order is for the supply of TOPAMAX 25 MG TABLET 60S, a pharmaceutical product. The contract has a period of performance through June 16, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC)...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,742.40 Firm Fixed Price Delivery Order is for the supply of TOPAMAX 50 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of June 13, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
- SPE2DB22D2214Indefinite Delivery Contract
- SPE2DB22D2214-SPE2DB24FS4XMDelivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Topamax 50mg tablets. The contract has a ceiling value of $8,017.03 and is a firm fixed price delivery order with a period of performance through May 17, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. This specific award does not have a set-aside designation.
Generated 8/15/24, 9:30 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.0k | 5/16/24 |